Shire shares rock­et up af­ter Take­da says it's pon­der­ing a takeover bid

8 years ago
Deals

He­mo­phil­ia groups warned of 5 deaths among pa­tients tak­ing Roche’s big new block­buster Hem­li­bra

8 years ago
R&D

Works in mice? It’s a win­ner for Ho­mol­o­gy as IPO reaps $144M haul, with biotech on a roll

8 years ago
Financing

Pre­clin­i­cal study shines a light on BET in­hibitors' po­ten­tial to pre­vent obe­si­ty-re­lat­ed can­cer growth

8 years ago
Discovery

Roivant bags Chi­na rights to Nabri­va's an­tibi­ot­ic; Sin­ga­pore’s Aslan Phar­ma lines up an $86M IPO to fund piv­otal ...

8 years ago
News Briefing

Chi­nese on­col­o­gy start­up Ada­gene clos­es $50M Se­ries C led by Se­quoia Cap­i­tal

8 years ago
Financing
Startups

Lies, damn lies and sta­tis­tics: A Stan­ford wiz says P<0.05 of­fers de­cep­tive ev­i­dence of bio­phar­mas' drug claims

8 years ago
Bioregnum
R&D

Iran­ian hack­ers steal aca­d­e­m­ic re­search worth bil­lions from US uni­ver­si­ties, pri­vate com­pa­nies

8 years ago
Pharma

Sin­ga­pore’s Aslan Phar­ma lines up an $86M IPO to fund piv­otal can­cer drug stud­ies

8 years ago
Financing

Re­shap­ing No­var­tis in­to a more ag­gres­sive phar­ma gi­ant, Vas Narasimhan bags a $13B con­sumer sale ahead of bolt-on ...

8 years ago
Pharma

Shang­hai drug­mak­er Hua hauls in $117M megaround, with plans for hefty Hong Kong IPO

8 years ago
Financing

Rev­enue down? No wor­ries for Gilead CEO Mil­li­gan as com­pen­sa­tion swells to $15.4M

8 years ago
People

Anap­tys­Bio clears an ear­ly hur­dle in low-stress PoC study for peanut al­ler­gy med -- big ques­tions go unan­swered

8 years ago
R&D

Chi­na's biotech pipeline is brim­ming with PD-1/L1 check­points. Are they re­al­ly need­ed?

8 years ago
China

With Big Phar­ma castoffs in hand, Mereo files for $81M IPO; Lon­don's Verona sees stock surge on PhI­Ib COPD da­ta

8 years ago
News Briefing

FDA hands a ‘break­through’ des­ig­na­tion to Seat­tle Ge­net­ics’ piv­otal-stage can­cer drug en­for­tum­ab

8 years ago
R&D

Bio­haven touts a pair of PhI­II wins for mi­graine pill, but shares ric­o­chet off of weak da­ta

8 years ago
R&D

Pro­tag­o­nist aborts lead ul­cer­a­tive col­i­tis pro­gram af­ter drug fiz­zles in PhI­Ib, stock craters

8 years ago
R&D

Gain­ing steam in PD-1/L1 race, Roche re­ports pos­i­tive PhI­II OS da­ta on Tecen­triq com­bo in NSCLC

8 years ago
R&D

Failed again: Sanofi's Abl­ynx re­ports PhII lu­pus flop

8 years ago
R&D

Beat­ing out mar­ket lead­ers in PhII, an­tibi­ot­ic-mak­er Al­le­cra read­ies for Phase III tri­als

8 years ago
R&D

With ma­jor fund­ing from No­var­tis, Sur­face On­col­o­gy launch­es a CD47 tri­al amid a swarm of ri­vals and files for $75M ...

8 years ago
Financing
Startups

Helsinn buys glob­al rights for skin can­cer drug from Acte­lion; Ake­bia reels in more cash for vadadu­s­tat; EMA slams ...

8 years ago
News Briefing

Backed in part by Roche, Den­mark's NMD gets $47M to run or­phan neu­ro­mus­cu­lar dis­ease tri­als

8 years ago
Financing
Startups
First page Previous page 1040104110421043104410451046 Next page Last page
A service from the Financial Times